CATALOGO DEI PRODOTTI DELLA RICERCA

MILELLA, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 13.743
NA - Nord America 13.657
AS - Asia 11.069
SA - Sud America 1.792
AF - Africa 393
OC - Oceania 43
Continente sconosciuto - Info sul continente non disponibili 9
AN - Antartide 1
Totale 40.707
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.279
RU - Federazione Russa 6.336
SG - Singapore 4.817
CN - Cina 2.568
IT - Italia 1.730
BR - Brasile 1.423
GB - Regno Unito 1.141
HK - Hong Kong 1.104
VN - Vietnam 1.062
DE - Germania 943
FR - Francia 904
IE - Irlanda 724
SE - Svezia 598
FI - Finlandia 505
KR - Corea 385
IN - India 215
NL - Olanda 209
CA - Canada 207
ID - Indonesia 207
AR - Argentina 123
JP - Giappone 113
PL - Polonia 112
MX - Messico 104
UA - Ucraina 104
ES - Italia 101
BD - Bangladesh 96
AT - Austria 94
ZA - Sudafrica 84
IQ - Iraq 71
TR - Turchia 71
EC - Ecuador 54
BJ - Benin 53
TG - Togo 51
CO - Colombia 50
NG - Nigeria 49
VE - Venezuela 43
AU - Australia 39
CZ - Repubblica Ceca 39
PK - Pakistan 37
EG - Egitto 30
MA - Marocco 30
UZ - Uzbekistan 30
SA - Arabia Saudita 28
TH - Thailandia 28
CL - Cile 26
IR - Iran 25
PY - Paraguay 25
BE - Belgio 23
CH - Svizzera 23
JO - Giordania 23
TN - Tunisia 22
LT - Lituania 21
AE - Emirati Arabi Uniti 20
MY - Malesia 20
UY - Uruguay 20
PH - Filippine 19
PE - Perù 18
NP - Nepal 17
KZ - Kazakistan 14
DZ - Algeria 13
KE - Kenya 13
AZ - Azerbaigian 12
HR - Croazia 12
KG - Kirghizistan 12
LV - Lettonia 11
PT - Portogallo 11
SN - Senegal 11
CR - Costa Rica 10
IL - Israele 10
AM - Armenia 9
DO - Repubblica Dominicana 9
GR - Grecia 9
HN - Honduras 9
RO - Romania 9
RS - Serbia 9
SK - Slovacchia (Repubblica Slovacca) 9
AL - Albania 7
AO - Angola 7
BO - Bolivia 7
BY - Bielorussia 7
CY - Cipro 7
DK - Danimarca 7
EU - Europa 7
GT - Guatemala 7
LU - Lussemburgo 7
NO - Norvegia 7
PS - Palestinian Territory 7
TW - Taiwan 7
BG - Bulgaria 6
ET - Etiopia 6
JM - Giamaica 6
MK - Macedonia 6
PA - Panama 6
KH - Cambogia 5
SI - Slovenia 5
SY - Repubblica araba siriana 5
BH - Bahrain 4
HU - Ungheria 4
LA - Repubblica Popolare Democratica del Laos 4
LB - Libano 4
Totale 40.630
Salva come PNG Salva come JPEG
Città #
Singapore 2.454
Moscow 2.052
Ashburn 2.013
Dallas 1.803
San Jose 1.639
Chandler 1.264
Hong Kong 1.088
Verona 785
Southend 738
Dublin 697
Beijing 490
The Dalles 443
Ho Chi Minh City 350
Munich 346
Woodbridge 334
Jacksonville 305
Los Angeles 276
New York 275
Lawrence 267
Princeton 267
Hanoi 225
Helsinki 205
Ann Arbor 197
Houston 196
Sindelfingen 185
Council Bluffs 181
Buffalo 157
Jakarta 155
São Paulo 153
Redondo Beach 150
Redmond 139
Jinan 136
Wilmington 136
Milan 125
London 122
Santa Clara 109
Tokyo 98
Turku 91
Frankfurt am Main 87
Nanjing 84
Shenyang 83
Orem 82
Columbus 81
Montreal 74
Nuremberg 74
Lappeenranta 72
Toronto 71
Chicago 70
Tianjin 69
Amsterdam 68
Warsaw 68
Seattle 63
Hebei 61
Da Nang 58
Meda 58
Johannesburg 57
Atlanta 54
Cotonou 53
Brooklyn 51
Lomé 51
Chennai 49
Guangzhou 47
Ningbo 46
San Francisco 46
Stockholm 46
Vienna 46
Abuja 45
Rio de Janeiro 45
Seoul 45
Changsha 44
Denver 44
Zhengzhou 40
Belo Horizonte 39
Haiphong 37
Hangzhou 36
Poplar 36
Boston 35
Mumbai 35
Rome 35
Boardman 34
Paris 33
Haikou 31
Kent 31
Nanchang 31
Baghdad 30
Barnet 30
Falkenstein 30
Mexico City 30
Shanghai 30
Taiyuan 30
Washington 30
Dong Ket 29
Phoenix 29
Biên Hòa 28
Tashkent 28
Curitiba 26
Madrid 26
Taizhou 26
Ankara 25
Redwood City 25
Totale 23.543
Salva come PNG Salva come JPEG
Nome #
Assessment of Psychological Burden in Individuals with Hereditary Risk of Pancreatic Cancer Under Surveillance: Evaluation of Distress 3 Years After Enrollment 328
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients 307
Genomic characterization of hepatoid tumors: context matters 260
"Running with cancer": A qualitative study to evaluate barriers and motivations in running for female oncological patients 248
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial 246
"Pure" hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations: a new entity among solid pseudopapillary neoplasms 215
Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models 214
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 212
Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease 204
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 200
A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma 199
Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg 198
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 194
Acinar Cystic Transformation of the Pancreas: Histomorphology and Molecular Analysis to Unravel its Heterogeneous Nature 192
Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice? 192
Long-Term Patient-Centred Follow-up in a Prospective Cohort of Patients with COVID-19 191
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 189
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 187
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 186
A Feasibility Study Investigating an Exercise Program in Metastatic Cancer Based on the Patient-Preferred Delivery Mode 185
A multimodal approach to cancer-related cachexia: from theory to practice 185
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 184
Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells 183
Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer 183
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 179
Extrahepatic Distal Cholangiocarcinoma vs. Pancreatic Ductal Adenocarcinoma: Histology and Molecular Profiling for Differential Diagnosis and Treatment 176
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 175
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss 175
Exercise prehabilitation in lung cancer: Getting stronger to recover faster 175
A cross-sectional study evaluating the exercise discussion with oncologist during cancer consultation: the CONNECT study 174
Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report 174
Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets 173
Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients 173
ERK 1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia 172
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 168
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models 167
An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen 166
Sex differences in oncogenic mutational processes 166
Development of Educational Print Materials for Physical Activity in Cancer: Evaluation of Readability and Suitability 165
Loss of FGFR4 promotes the malignant phenotype of PDAC 164
Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: A retrospective, multicenter analysis 164
Do immune checkpoint inhibitors need new studies methodology? 163
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done 162
Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer 162
Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma 161
Exercise levels and preferences in cancer patients: a cross-sectional study 161
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 161
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients 161
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 159
Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours 158
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 157
Psychological impact of Covid-19 pandemic on oncological patients: a survey in Northern Italy 157
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned 157
A qualitative study exploring the experiences and perspectives of patients with cancer attending a 12-week exercise program 156
Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors 156
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome 155
Integrative characterization of intraductal tubulopapillary neoplasm (ITPN) of the pancreas and associated invasive adenocarcinoma 155
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 154
Infections and Immunotherapy in Lung Cancer: A Bad Relationship? 154
Targeting KRAS: The Elephant in the Room of Epithelial Cancers 154
From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer 153
Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions 153
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer 153
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer 153
JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer 152
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 152
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer 151
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities 151
Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial 151
Exercise for counteracting post-acute COVID-19 syndrome in patients with cancer: an old but gold strategy? 151
Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications 150
A cross-sectional study exploring the perception of exercise oncology in the Italian population 150
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 150
Pan-cancer analysis of whole genomes 150
Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas 149
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis 149
Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report 149
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples 147
Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites 147
ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR 146
Interleukin-6: A New Marker of Advanced-Sarcopenic HCC Cirrhotic Patients 145
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 145
Dosimetric Feasibility Study of Dose Escalated Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients: It Is Time to Raise the Bar 145
Muscle derangement and alteration of the nutritional machinery in NSCLC 144
Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study 144
Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder 143
Risk and severity of SARS-CoV-2 infection in breast cancer patients undergoing a structured infection screening program at the University and Hospital Trust of Verona 143
Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer 142
Case report: Male genital system, soft tissue and myocardial metastases in a patient with exon 11-mutated GIST of unknown origin 142
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 141
DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association 141
A Journey through the Multifaceted Landscape of Prostate Cancer: from Bench to Bedside Studies 141
Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic Implications 140
Exercise and anemia in cancer patients: could make the difference? 140
Effect of exercise on functional capacity in patients with advanced cancer: A meta-analysis of randomized controlled trials 140
Predictive and prognostic effect of computed tomography-derived body composition analysis during neoadjuvant chemotherapy for operable and locally advanced breast cancer 139
Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface 138
Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study 138
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma 136
18F-FDG and 68Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study 136
Totale 16.821
Salva come PNG Salva come JPEG
Categoria #
all - tutte 149.966
article - articoli 148.680
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 290
patent - brevetti 0
selected - selezionate 0
volume - volumi 996
Totale 299.932
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021206 0 0 0 0 0 0 0 0 0 25 110 71
2021/20221.789 110 378 60 108 46 22 37 103 59 37 310 519
2022/20234.070 290 364 383 714 323 1.057 61 223 440 49 105 61
2023/20242.607 91 167 234 360 225 356 206 191 56 126 419 176
2024/20257.962 438 354 332 1.393 349 302 437 439 1.112 629 730 1.447
2025/202621.742 1.501 1.258 2.031 3.586 5.544 1.347 2.020 1.367 1.845 1.243 0 0
Totale 41.245